| The acute effects of cannabinoids on memory in humans: a review M Ranganathan, DC D’Souza Psychopharmacology 188, 425-444, 2006 | 662 | 2006 |
| Cannabis and psychosis/schizophrenia: human studies DC D’Souza, RA Sewell, M Ranganathan European archives of psychiatry and clinical neuroscience 259, 413-431, 2009 | 393 | 2009 |
| Blunted psychotomimetic and amnestic effects of Δ-9-tetrahydrocannabinol in frequent users of cannabis DC D'souza, M Ranganathan, G Braley, R Gueorguieva, Z Zimolo, ... Neuropsychopharmacology 33 (10), 2505-2516, 2008 | 330 | 2008 |
| Clinical and preclinical evidence for functional interactions of cannabidiol and Δ9-tetrahydrocannabinol DL Boggs, JD Nguyen, D Morgenson, MA Taffe, M Ranganathan Neuropsychopharmacology 43 (1), 142-154, 2018 | 253 | 2018 |
| The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial DL Boggs, T Surti, A Gupta, S Gupta, M Niciu, B Pittman, ... Psychopharmacology 235, 1923-1932, 2018 | 238 | 2018 |
| Rapid changes in cannabinoid 1 receptor availability in cannabis-dependent male subjects after abstinence from cannabis DC D’Souza, JA Cortes-Briones, M Ranganathan, H Thurnauer, ... Biological psychiatry: cognitive neuroscience and neuroimaging 1 (1), 60-67, 2016 | 219 | 2016 |
| Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled … DC D'Souza, J Cortes-Briones, G Creatura, G Bluez, H Thurnauer, ... The Lancet Psychiatry 6 (1), 35-45, 2019 | 155 | 2019 |
| Human laboratory studies on cannabinoids and psychosis M Sherif, R Radhakrishnan, DC D’Souza, M Ranganathan Biological psychiatry 79 (7), 526-538, 2016 | 151 | 2016 |
| Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Δ-9-tetrahydrocannabinol in humans DC D’Souza, G Braley, R Blaise, M Vendetti, S Oliver, B Pittman, ... Psychopharmacology 198, 587-603, 2008 | 151 | 2008 |
| Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin CG Abdallah, LA Averill, R Gueorguieva, S Goktas, P Purohit, ... Neuropsychopharmacology 45 (6), 990-997, 2020 | 143 | 2020 |
| Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans M Ranganathan, A Schnakenberg, PD Skosnik, BM Cohen, B Pittman, ... Biological psychiatry 72 (10), 871-879, 2012 | 137 | 2012 |
| The effects of cannabinoids on serum cortisol and prolactin in humans M Ranganathan, G Braley, B Pittman, T Cooper, E Perry, J Krystal, ... Psychopharmacology 203, 737-744, 2009 | 135 | 2009 |
| Association of ketamine with psychiatric symptoms and implications for its therapeutic use and for understanding schizophrenia: a systematic review and meta-analysis K Beck, G Hindley, F Borgan, C Ginestet, R McCutcheon, S Brugger, ... JAMA network open 3 (5), e204693-e204693, 2020 | 131 | 2020 |
| Medical marijuana: is the cart before the horse? DC D'Souza, M Ranganathan Jama 313 (24), 2431-2432, 2015 | 128 | 2015 |
| Cannabinoids and psychosis RA Sewell, M Ranganathan, DC D'Souza International Review of Psychiatry 21 (2), 152-162, 2009 | 125 | 2009 |
| Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Δ9-THC in humans DC D'souza, DJ Fridberg, PD Skosnik, A Williams, B Roach, N Singh, ... Neuropsychopharmacology 37 (7), 1632-1646, 2012 | 120 | 2012 |
| Reduced brain cannabinoid receptor availability in schizophrenia M Ranganathan, J Cortes-Briones, R Radhakrishnan, H Thurnauer, ... Biological psychiatry 79 (12), 997-1005, 2016 | 110 | 2016 |
| Behavioral, cognitive and psychophysiological effects of cannabinoids: relevance to psychosis and schizophrenia RA Sewell, PD Skosnik, I Garcia-Sosa, M Ranganathan, DC D'Souza Brazilian Journal of Psychiatry 32, 515-530, 2010 | 95* | 2010 |
| Acute effects of THC on time perception in frequent and infrequent cannabis users RA Sewell, A Schnakenberg, J Elander, R Radhakrishnan, A Williams, ... Psychopharmacology 226, 401-413, 2013 | 88 | 2013 |
| Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidence DC D'souza, N Singh, J Elander, M Carbuto, B Pittman, JU De Haes, ... Neuropsychopharmacology 37 (4), 1036-1046, 2012 | 74 | 2012 |
